Guess which small cap ASX stock could rise 50% in a 'transformational year'

This small cap has been tipped to rise materially from current levels. But why?

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're not averse to investing at the small side of the market, then it could be worth checking out Aroa Biosurgery Ltd (ASX: ARX).

That's because analysts at Bell Potter believe the small cap ASX stock could rise materially from current levels.

What is this small cap ASX stock?

Aroa Biosurgery is a soft-tissue regeneration company. It states that it is committed to "unlocking regenerative healing for everybody."

It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. The small cap ASX stock's products are developed from a proprietary AROA ECM technology platform. It is a novel extracellular matrix biomaterial derived from ovine forestomach.

'A potentially transformational year'

Bell Potter believes that FY 2025 could be a transformational year for the company that could see its first profit and free cash flow. It said:

FY25 is a potentially transformational year for ARX with the likelihood of a maiden profit and positive free cash flows. We believe these have been the drivers of the resurgence in market value of the stock, spurned on by the positive revenue and earnings guidance provided at the recent full year update (for FY24).

Another positive is that there could soon be some clinical trial data available that the broker feels could be supportive of sales. It adds:

While the ARX products appear widely regarded and have been the subject of literally dozens of published articles, the absence of gold standard data from randomised clinical trials is a gap. Recruitment of clinical trials in the key area of lower limb salvage and large trauma wounds is problematic, however, to this end the company has recently completed enrolment of its Myriad Augmented Soft Tissue Regeneration Registry (MASTRR) with clinical data expected to commence in late FY25.

In addition, there's potential for another clinical trial to open up the company to a market with a US$1 billion opportunity. The broker said:

In addition, ARX will shortly complete recruitment of its 120 patient randomised study in diabetic foot ulcer (DFU) patients investigating the wound healing properties of its Symphony product with headline data due in 2H FY25. Data from a recent retrospective real world study is highly supportive of the wound healing properties of Myriad in severe DFU cases. A successful outcome (which we believe is likely) may unlock the market in outpatient wound care for DFU's where TAM is estimated at >US$1.0bn.

Big return potential

This morning, Bell Potter has reiterated its buy rating and 90 cents price target on the small cap ASX stock.

Based on its current share price of 60 cents, this implies potential upside of 50% for investors over the next 12 months.

Overall, this could make Aroa Biosurgery worth a closer look. Particularly if you're looking for some small cap exposure.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

Two brokers analysing stocks.
Small Cap Shares

Broker tips these 3 ASX small-cap healthcare stocks to rise 56%, 79% and 130%

These 3 ASX small-cap stocks could deliver substantial returns.

Read more »

growth charts with small cap written on a sticky note
Small Cap Shares

Expert names 3 ASX small-cap stocks to buy in July

ASX small-cap stocks have greater ability to generate outsized returns, but can be difficult to discover.

Read more »

Two funeral workers with a laptop surrounded by cofins.
Small Cap Shares

Why I think this ASX small-cap stock is a bargain at $4.74

This business has excellent long-term growth potential.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Small Cap Shares

Why I think this ASX small-cap stock is a bargain at $3.36

This business could continue revving higher…

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Small Cap Shares

Why this ASX small-cap stock has significant potential

This business is delivering significant growth.

Read more »

Five young boys wearing small caps sit on a bench together watching a baseball game.
Small Cap Shares

5 ASX small-cap shares that screamed 114% to 362% higher in FY25

Here are some examples of ASX small-cap shares that experienced outstanding price growth in FY25.

Read more »

Three young people in business attire sit around a desk and discuss.
Small Cap Shares

Tiny tech: 3 ASX small-cap shares with new ratings

Toby Grimm of Baker Young and Peter Day of Sequoia Wealth Management share their new ratings.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Small Cap Shares

Hidden gems: Experts name 3 ASX small-cap shares to buy now

One of these ASX small-cap shares has risen by a staggering 1,687% over the past 12 months.

Read more »